Air T ( AIRT) shares jumped nearly 9% in after-hours trading Tuesday after the Maiden, N.C.-based air-delivery company announced that the Air Force ordered about $13.8 million worth of its mobile de-icing trucks -- 43 in total. Shares were rising 67 cents to $8.20 in recent extended trading.

Sapient ( SAPE), a business-software and marketing-services firm, said its non-GAAP income from continuing operations totaled $7.9 million, or 6 cents a share, in the fourth quarter -- a 4-cent per-share drop from last year, but 4 cents higher than Wall Street expectations, according to Thomson Financial. Revenue surged 38% to $119.2 million, handily beating the $110.4 million consensus.

In 2007 the Cambridge, Mass., company expects sales in excess of $500 million. Analysts are looking for $491.2 million. Shares were adding 49 cents, or 8.2%, to $6.50.

Gymboree ( GYMB) got a lift after the children's-apparel retailer posted a profit of 84 cents a share (excluding a 2-cent settlement-related charge) in the quarter ended Feb. 3, which sprints past Wall Street's 72-cent per-share projections. Gymboree stock was gaining $2.28, or 6.5%, to $37.42.

Horse race-betting Web site ( UBET) rose after adjusted losses came to 3 cents a share, which beat ithe Street's call for 6-cent losses. Shares of the Woodland Hills, Calif., company were up 11 cents, or 3.9%, to $2.95.

Diamond ( DTPI), a Chicago-based management-consulting firm, slumped after tamping down its guidance for the quarter already in progress. It now projects earnings of between 6 cents and 7 cents a share, compared with its prior outlook of 8 cents to 10 cents. Wall Street is seeking 9 cents a share.

Revenue should now range between $41.5 million and $42.5 million -- at least $3.8 million under targets -- compared with the company's previous forecast of $44 million to $47 million. Shares were off $1.65, or 11.1%, to $13.20.

Maxygen ( MAXY) slid after Switzerland's Roche decided to terminate its yearlong agreement with the California-based biotech regarding development of Maxy-VII, a treatment for acute bleeding indications, as of April 12.

Roche, which was to lead late-stage clinical development of the drug candidate, cited the companies' inability to perform adequate de-risking prior to clinical trials. It has now relinquished all of its rights to the product back to Maxygen. The latter was down 75 cents, or 7.1%, to $9.75.